Current U.S. prescribing information for Rezdiffra describes resmetirom as an oral, once-daily medicine that can be taken with or without food. The tablets should be swallowed whole and should not be split, crushed or chewed.
Because the specific Resiliva formulation has not been independently verified, readers should follow the instructions supplied with the actual Resiliva product and the applicable local prescribing information.
General administration principles
- Take resmetirom exactly as prescribed.
- The U.S. reference-product regimen is once daily.
- It may be taken with or without food under current U.S. labeling.
- Swallow Rezdiffra tablets whole.
- Do not independently alter the prescribed dose.
- Do not substitute another resmetirom product without appropriate professional guidance.
Missed dose
The exact missed-dose instructions should be taken from the product-specific prescribing information.
Patients should not double the next dose unless specifically instructed by a healthcare professional.
Monitoring
Treatment may require monitoring of liver-related symptoms and laboratory findings, particularly because hepatotoxicity is an identified warning. Gallbladder symptoms also require clinical attention.
Medicines taken at the same time
Resmetirom can interact with certain medicines. Current U.S. labeling specifically addresses strong and moderate CYP2C8 inhibitors, statins and CYP2C8 substrates.